<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="brief-report" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title>Frontiers in Immunology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Immunol.</abbrev-journal-title>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fimmu.2024.1374818</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology</subject>
<subj-group>
<subject>Brief Research Report</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Lung ILC2s are activated in BALB/c mice born to immunized mothers despite complete protection against respiratory syncytial virus</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Kosanovich</surname>
<given-names>Jessica L.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1007902"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Eichinger</surname>
<given-names>Katherine M.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lipp</surname>
<given-names>Madeline A.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gidwani</surname>
<given-names>Sonal V.</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/972092"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Brahmbhatt</surname>
<given-names>Devarshi</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yondola</surname>
<given-names>Mark A.</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1321357"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chi</surname>
<given-names>David H.</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Perkins</surname>
<given-names>Timothy N.</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1659550"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Empey</surname>
<given-names>Kerry M.</given-names>
</name>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
<xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/970332"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, University of Pittsburgh</institution>, <addr-line>Pittsburgh, PA</addr-line>, <country>United States</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Center for Clinical Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, University of Pittsburgh</institution>, <addr-line>Pittsburgh, PA</addr-line>, <country>United States</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Calder Biosciences Inc.</institution>, <addr-line>New York, NY</addr-line>, <country>United States</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Division of Pediatric Otolaryngology, Children&#x2019;s Hospital of Pittsburgh, University of Pittsburgh School of Medicine</institution>, <addr-line>Pittsburgh PA</addr-line>, <country>United States</country>
</aff>
<aff id="aff5">
<sup>5</sup>
<institution>Department of Pathology, University of Pittsburgh School of Medicine</institution>, <addr-line>Pittsburgh, PA</addr-line>, <country>United States</country>
</aff>
<aff id="aff6">
<sup>6</sup>
<institution>Department of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, University of Pittsburgh</institution>, <addr-line>Pittsburgh, PA</addr-line>, <country>United States</country>
</aff>
<aff id="aff7">
<sup>7</sup>
<institution>Department of Immunology, University of Pittsburgh School of Medicine, University of Pittsburgh</institution>, <addr-line>Pittsburgh, PA</addr-line>, <country>United States</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Stephania Cormier, Louisiana State University, United States</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Luan D. Vu, Louisiana State University, United States</p>
<p>Hongyu Wu, National Institute of Allergy and Infectious Diseases (NIH), United States</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Kerry M. Empey, <email xlink:href="mailto:kme33@pitt.edu">kme33@pitt.edu</email>
</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>17</day>
<month>05</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>15</volume>
<elocation-id>1374818</elocation-id>
<history>
<date date-type="received">
<day>22</day>
<month>01</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>03</day>
<month>05</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2024 Kosanovich, Eichinger, Lipp, Gidwani, Brahmbhatt, Yondola, Chi, Perkins and Empey</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Kosanovich, Eichinger, Lipp, Gidwani, Brahmbhatt, Yondola, Chi, Perkins and Empey</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Activated lung ILC2s produce large quantities of IL-5 and IL-13 that contribute to eosinophilic inflammation and mucus production following respiratory syncytial virus infection (RSV). The current understanding of ILC2 activation during RSV infection, is that ILC2s are activated by alarmins, including IL-33, released from airway epithelial cells in response to viral-mediated damage. Thus, high levels of RSV neutralizing maternal antibody generated from maternal immunization would be expected to reduce IL-33 production and mitigate ILC2 activation. Here we report that lung ILC2s from mice born to RSV-immunized dams become activated despite undetectable RSV replication. We also report, for the first time, expression of activating and inhibitory Fcgamma receptors on ILC2s that are differentially expressed in offspring born to immunized versus unimmunized dams. Alternatively, ex vivo IL-33-mediated activation of ILC2s was mitigated following the addition of antibody: antigen immune complexes. Further studies are needed to confirm the role of Fcgamma receptor ligation by immune complexes as an alternative mechanism of ILC2 regulation in RSV-associated eosinophilic lung inflammation.</p>
</abstract>
<kwd-group>
<kwd>RSV</kwd>
<kwd>maternal immunization</kwd>
<kwd>ILC2</kwd>
<kwd>Fcgamma receptors</kwd>
<kwd>IL-33</kwd>
</kwd-group>
<contract-num rid="cn001">1R43AI140941-01, R21AI171241</contract-num>
<contract-num rid="cn002">1S10OD011925-01</contract-num>
<contract-num rid="cn003">R03-RHD080874A</contract-num>
<contract-sponsor id="cn001">National Institute of Allergy and Infectious Diseases<named-content content-type="fundref-id">10.13039/100000060</named-content>
</contract-sponsor>
<contract-sponsor id="cn002">National Institutes of Health<named-content content-type="fundref-id">10.13039/100000002</named-content>
</contract-sponsor>
<contract-sponsor id="cn003">Eunice Kennedy Shriver National Institute of Child Health and Human Development<named-content content-type="fundref-id">10.13039/100009633</named-content>
</contract-sponsor>
<counts>
<fig-count count="4"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="50"/>
<page-count count="10"/>
<word-count count="5764"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>Viral Immunology</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<label>1</label>
<title>Introduction</title>
<p>The neonatal period of lung development is a formative timeframe responsible for establishing a tissue resident ILC2 pool that persists through adulthood (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>). ILC2 precursors seed the lungs during prenatal development and expand to adult levels in the first 2 weeks of life. During this time, ILC2s adopt a lung-specific transcriptional signature that dictates subsequent activation, expansion, and maintenance (<xref ref-type="bibr" rid="B1">1</xref>). These neonatally-established ILC2s constitute the majority of the adult ILC2 pool and represent the predominant ILC2 population that expands in response to stimulation (<xref ref-type="bibr" rid="B1">1</xref>). Importantly, ILC2s trained during neonatal activation are more functionally competent upon re-stimulation, demonstrating more vigorous responses to stimulation than newly established adult ILC2s (<xref ref-type="bibr" rid="B2">2</xref>). Consistent with this work, we previously identified a hyperresponsive ILC2 (hILC2) population in maternally vaccinated offspring following secondary exposure to respiratory syncytial virus (RSV) (<xref ref-type="bibr" rid="B3">3</xref>). As a prior stimulation is necessary to &#x201c;train&#x201d; a more functionally competent ILC2 population in adulthood, the presence of hILC2s in offspring born to dams immunized with an adjuvated prefusion RSV F vaccine, led us to theorize that ILC2s were activated during primary neonatal RSV exposure in the presence of RSV-neutralizing maternal antibody (matAb). Here we describe the role of antibody:antigen immune complexes in regulating lung ILC2 activation and propose this as an alternative mechanism by which ILC2s may be activated in offspring born to RSV-immunized dams.</p>
</sec>
<sec id="s2" sec-type="materials|methods">
<label>2</label>
<title>Materials and methods</title>
<sec id="s2_1">
<label>2.1</label>
<title>Maternal immunization, intranasal RSV infections, and treatments</title>
<p>Animal studies were carried out in accordance with the University of Pittsburgh&#x2019;s IACUC guidelines for the use and care of laboratory animals. Female Balb/cJ mice (7-8 weeks of age; The Jackson Laboratory, Bar Harbor, ME) were primed one week prior to breeding via intramuscular (IM) hind-limb injection with 50&#x3bc;L of PBS alone or the stabilized RSV prefusion F protein, DS-Cav1 (10&#x3bc;g per mouse; a gift from Jason McLellan and supplied by Calder Biosciences, Brooklyn, NY) formulated with Alum (100&#x3bc;g/mouse; Alhydrogel, <italic>In vivo</italic>gen; <xref ref-type="fig" rid="f1">
<bold>Figures&#xa0;1B&#x2013;D</bold>
</xref>, <xref ref-type="fig" rid="f2">
<bold>2</bold>
</xref>, <xref ref-type="fig" rid="f3">
<bold>3</bold>
</xref>, <xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figures S1A, B</bold>
</xref>) or Advax (1mg/mouse; Vaxine, Pty, Ltd; <xref ref-type="fig" rid="f1">
<bold>Figures&#xa0;1E&#x2013;H</bold>
</xref>, <xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figure S1C</bold>
</xref>). One week later, mice were bred, as previously described (<xref ref-type="bibr" rid="B4">4</xref>) and in the second week of gestation (3 weeks post-prime), mice were boosted IM with their respective vaccine. Offspring born to PBS-vaccinated dams are referred to as mVeh, while those born to adjuvanted DS-Cav1 vaccinated dams are labeled as mPreF.</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>ILC2 activation occurs in mPreF pups despite complete protection from replicating RSV and similar levels of IL-33. 1 week prior to parturition, pregnant Balb/c mice completed a 2-dose vaccination series of vehicle (mVeh) or PreF/Adjuvant (mPreF). At PND6, a cohort of mVeh and mPreF pups were culled for pre-challenge serum antibody analysis while a second cohort of pups were intranasally exposed to 5x10<sup>5</sup> PFU/gm RSV L19 and culled at 4dpe for viral titer and ILC2 analysis <bold>(A)</bold>. Pre-challenge serum from mVeh and mPreF pups was analyzed for RSV neutralizing antibody <bold>(B)</bold>. At 1dpe, left lungs were analyzed for viral titers <bold>(C)</bold> and right lung homogenate was processed for IL-33 quantification <bold>(D)</bold>. At 4dpe, left lungs were analyzed for viral titers <bold>(E)</bold>, while total lung ILC2s <bold>(F)</bold> and frequency of IL-13<sup>+</sup> ILC2s <bold>(G)</bold> and IL-5<sup>+</sup> ILC2s <bold>(H)</bold> were analyzed from the right lungs. Pups were born to dams immunized with preF/Advax <bold>(B&#x2013;D)</bold> or preF/Alum (<bold>E&#x2013;H</bold>). Data are represented as mean &#xb1; SEM (n=4-8 mice per group). Nonlinear regression was used to obtain IC50 values with the dotted line indicating the lower limit of quantification <bold>(B)</bold>. Statistical significance was calculated using an unpaired t-test. **p &#x2264; 0.01, ***p &#x2264; 0.001, and ****p &#x2264; 0.0001 (<bold>C-H</bold>). Created with <uri xlink:href="https://BioRender.com">BioRender.com</uri>.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1374818-g001.tif"/>
</fig>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>Passive transfer of RSV-neutralizing antibody leads to ILC2 activation. Adult Balb/cJ mice were administered heat-inactivated serum from PreF/Alum-vaccinated dams one day prior to intranasal exposure to MEM (pPreF-Veh) or 5x10<sup>5</sup> PFU/gm RSV L19 (pPreF-RSV). At 4dpe, mice received an intraperitoneal injection of Bodipy FL C16 one hour prior to sacrifice, at which time lungs were harvested for ILC2 analysis <bold>(A)</bold>. Left lungs were collected from non-immunized (RSV) and passively immunized (pPreF-RSV) adult mice for viral titer analysis <bold>(B)</bold>. Dotted line represents the lower limit of viral quantification defined as less than five plaques in a well. Total ILC2s <bold>(C)</bold>, IL-13+ ILC2s <bold>(D)</bold> and IL-5+ ILC2s <bold>(E)</bold>, as well as the frequency of Bodipy+ ILC2s <bold>(F, G)</bold> were quantified at 4dpe. Representative histogram depicting the percentage of cells vs. Bodipy signal is shown - Bodipy negative ILC2s (light grey), pPreF-Veh ILC2s (dark gray), and pPreF-RSV (red) <bold>(G)</bold>. Data are represented as mean &#xb1; SEM (n=2-7 mice per group). Statistical significance was calculated using an unpaired t-test <bold>(B&#x2013;F)</bold>. Statistical significance was calculated using an unpaired t-test. **p &#x2264; 0.01. Created with <uri xlink:href="https://BioRender.com">BioRender.com</uri>.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1374818-g002.tif"/>
</fig>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>Fc&#x3b3;Rs are expressed on murine and human airway ILC2s. mVeh and mPreF offspring were generated and infected as described in <xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>; all dams were immunized with PreF adjuvanted with alum. At 4dpe, right lungs were harvested for analysis of Fc&#x3b3;RIII <bold>(A&#x2013;C, G)</bold>, Fc&#x3b3;RIIb <bold>(D&#x2013;F, H)</bold>, and Fc&#x3b3;RI <bold>(I)</bold> expression. Fluorescence minus one (FMO) controls were used to determine positive Fc&#x3b3;RIII and Fc&#x3b3;RIIb staining <bold>(A,D)</bold> and representative contour plots from mVeh and mPreF offspring are shown <bold>(B, C, E, F)</bold>. The frequencies of Fc&#x3b3;RIII<sup>+</sup> <bold>(G)</bold>, Fc&#x3b3;RIIb<sup>+</sup> <bold>(H)</bold> and Fc&#x3b3;RI<sup>+</sup> <bold>(I)</bold> ILC2s were quantified and the ratio of Fc&#x3b3;RIII<sup>+</sup>:Fc&#x3b3;RIIb<sup>+</sup> was calculated <bold>(J)</bold>. The nasopharyngeal lavage fluid of pediatric patients undergoing adenoidectomies (n=3) was analyzed for ILC2 expression of Fc&#x3b3;RIII <bold>(K, L)</bold> and Fc&#x3b3;RII <bold>(M, N)</bold>. FMO controls were used to determine positive Fc&#x3b3;RIII <bold>(K)</bold> and Fc&#x3b3;RII staining <bold>(N)</bold>. Data are represented as mean &#xb1; SEM (n=5 mice per group). Statistical significance was calculated using an unpaired t-test <bold>(G&#x2013;I)</bold> or Wilcoxon signed rank test <bold>(J)</bold>. ns, non-significant, *p &#x2264; 0.05, **p &#x2264; 0.01, and ****p &#x2264; 0.0001.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1374818-g003.tif"/>
</fig>
<p>For primary RSV infections, mice were intranasally (i.n.) infected with RSV L19 (provided by Dr. Martin Moore) at an infectious dose of 5x10<sup>5</sup> plaque forming units (PFU) per gram of body weight at post-natal day (PND) 5-6 under isoflurane anesthesia, as previously described (<xref ref-type="bibr" rid="B4">4</xref>). At 1- and 4-days post-exposure, mice were culled using 100% isoflurane and cervical dislocation. RSV L19 was propagated and viral titers quantified as previously described (<xref ref-type="bibr" rid="B5">5</xref>).</p>
<p>For fatty acid uptake analysis, 50&#x3bc;g of Bodipy FL C<sub>16</sub> (ThermoScientific) resuspended in DMSO was administered via intraperitoneally 60 minutes prior to sacrifice, as previously described (<xref ref-type="bibr" rid="B6">6</xref>).</p>
</sec>
<sec id="s2_2">
<label>2.2</label>
<title>RSV-neutralizing antibody &#x2013; Renilla luciferase RSV reporter assay</title>
<p>Pre-challenge blood was collected via terminal bleed from non-exposed infants at PND5-6. In adult offspring, pre-challenge blood was collected via submandibular bleed immediately prior to RSV exposure and separated using Gel-Z serum separator tubes (Sarstedt). Serum was stored at -80&#xb0;C until heat-inactivation (56&#xb0;C for 30 minutes) and Renilla Luciferase RSV Reporter Assay was performed (<xref ref-type="bibr" rid="B7">7</xref>&#x2013;<xref ref-type="bibr" rid="B10">10</xref>). Briefly, heat-inactivated serum was serially diluted in phenol-free MEM supplemented with 5% FBS and Pen/Strep before incubation in 96-well plate format with 100 PFU/well RSV L19-Renilla Luciferase virus (a gift from Martin Moore) for 2 hours at 37&#xb0;C/5% CO<sub>2</sub>. After incubation, HEp-2 cells were trypsinized and a total of 2.5x10<sup>4</sup> cells were added to 25&#x3bc;L FBS+Pen/Strep-containing phenol-free MEM and incubated for 64-66 hours at 37&#xb0;C/5% CO<sub>2</sub>. After incubation, luciferase readouts were obtained using the Renilla-Glo Luciferase Assay system (Promega), according to manufacturer&#x2019;s instructions. After incubation, luciferase activity was measured using a Novostar plate reader. The RSV luciferase assay generates a sigmoidal luminescence readout from which the midpoint (IC50) is calculated by nonlinear regression. The limit of quantification for the neutralization assay is set at the midpoint between the highest dilution and the next dilution in the 3-fold dilution series, as described previously (<xref ref-type="bibr" rid="B7">7</xref>&#x2013;<xref ref-type="bibr" rid="B10">10</xref>). Serum dilutions were used to generate a full sigmoidal-shaped luminescence curve for the vaccinated animals and control samples are diluted equivalently to allow for cross-comparison. The limit of blank (cells only control) was previously determined for this assay to be 1826 RLU and the average of the virus-only control lanes included on each plate in the assay was 60,630 RLU. Since no Veh control samples achieved a signal less than 80% of the virus-only control even at their highest concentration, no IC50 could be determined for these samples and the lowest serum dilution used in the assay is reported as the neutralization titer, in this case 1:100 (marked by dashed line). All plates were run in duplicate and averaged.</p>
</sec>
<sec id="s2_3">
<label>2.3</label>
<title>Cell preparation, stimulation, and flow cytometry</title>
<p>Right lung lobes were collected, processed, and enumerated, as previously described (<xref ref-type="bibr" rid="B11">11</xref>). For ILC2 stimulation, lung homogenate was stimulated with PMA (30 ng/mL, Sigma Aldrich), ionomycin (500 ng/mL, Sigma Aldrich), and Brefeldin A (1:1000) in 10% RPMI at 37&#xb0;C for 3 hours. Following stimulation, lung cells were surface stained, then fixed and permeabilized using BD Cytofix/Cytoperm&#x2122; kit (BD Biosciences) prior to intracellular cytokine staining. ILC2s were identified as previously described (<xref ref-type="bibr" rid="B3">3</xref>). Specifically, lung cells were surface stained with CD16/32 (Fc block; 2.4G2), LIVE/DEAD&#x2122; Fixable Blue Dead Cell Stain Kit, Lineage Cocktail (CD3 (17A2), Ly6G/Ly6C (RB6-8C5), CD11b (M1/70), CD45R (RA3-6B2), TER-119 (Ter-119)), CD49b (DX5), CD45 (30-F11), ST2 (DIH9), ICOS (C398.4A), CD127 (A7R34) and CD25 (PC61) and intracellularly stained for IL-5 (TRFK5) and IL-13 (ebio13A), as previously reported (<xref ref-type="bibr" rid="B3">3</xref>). Samples were run on a BD Fortessa or Cytek Aurora managed by the United Flow Core of the University of Pittsburgh. Data was analyzed using FlowJo V10 software (FLOWJO, LLC, OR).</p>
</sec>
<sec id="s2_4">
<label>2.4</label>
<title>ILC2 isolation and culturing</title>
<p>Right and left lungs from na&#xef;ve adult mice were excised, minced, and digested in digestion media (Liberase, 2.5mg/500&#x3bc;L, MilliporeSigma; DNase, 1000&#x3bc;g/mL, Sigma Aldrich; Collagenase, 1mg/mL) for 45 minutes at 37&#xb0;C/5% CO<sub>2</sub>. For complete homogenization, digested lungs were pushed through a 70&#x3bc;M mesh strainer and washed with HBSS. Lungs were then passed through a 40&#x3bc;M mesh strainer to generate a single cell suspension and subjected to ACK lysing for removal of red blood cells. Cells were then combined and resuspended in cILC2 media (RPMI 1640, 10% FBS, 100U/mL Pen/Strep, 1x non-essential amino acids (Gibco), 1mM sodium pyruvate (Lonza), supplemented with 10ng/&#x3bc;L recombinant IL-2 (rIL2, BioLegend). Cells were then seeded into 150mm petri dishes and rested for 3-4 hours at 37&#xb0;C/5% CO<sub>2</sub>, allowing for removal of adherent epithelial and innate immune cells. After incubation, enriched non-adherent cells were collected and enumerated before surface staining with ILC2 sorting antibody cocktail, as previously described, in the presence of Fc block, as previously described (<xref ref-type="bibr" rid="B3">3</xref>). Cells were not fixed, as they were to be used for ex vivo stimulation studies. Cells were sorted on a FACS Aria with the assistance of the University of Pittsburgh United Flow Core personnel and defined as CD45<sup>+</sup> Lineage<sup>-</sup> CD49b<sup>-</sup> CD117<sup>-</sup> CD127<sup>+</sup> ST2<sup>+</sup>, as previously described (<xref ref-type="bibr" rid="B2">2</xref>). Cells were sorted into cILC2 media supplemented with 50% FBS, to reduce cell shearing. After sorting, cells were enumerated and seeded into 96-well plates at a concentration of 5,000 ILC2s/well and rested overnight at 37&#xb0;C/5% CO<sub>2</sub> in cILC2 media until stimulation.</p>
</sec>
<sec id="s2_5">
<label>2.5</label>
<title>Immune complex generation and ex vivo ILC2 stimulation</title>
<p>To prepare Ab:RSV immune complexes (ICs), working stock RSV L19 was diluted in cILC2 media to achieve a concentration of 25,000 PFUs/60&#x3bc;L. Heat-inactivated serum from PreF/Alum-vaccinated dams was pooled and diluted in cILC2 media to a final dilution of 1:10. This optimized serum dilution was determined by incubating various dilutions of PreF/Alum serum with 25,000 PFUs of RSV and overlayed onto confluent HEp-2 cells and performing a standard plaque assay as previously described (<xref ref-type="bibr" rid="B5">5</xref>). A 1:10 dilution of pooled Alum serum resulted in undetectable RSV plaques and was the optimized serum dilution used for IC generation. To a 96-well flat-bottom plate (Corning), diluted PreF/Alum serum was incubated with 25,000 PFUs for 1 hour at 37&#xb0;C/5% CO<sub>2</sub> with intermittent shaking. At the end of incubation, pre-formed Ab : RSV ICs were added to rested ILC2s alone or in combination with rIL-33 (10ng/mL, BioLegend). Stimulated ILC2s were incubated at 37&#xb0;C/5% CO<sub>2</sub> for the indicated days; supernatants were then harvested and preserved for cytokine quantification.</p>
<p>To prepare Ova ICs, purified ovalbumin (Ova, Invitrogen) was incubated with purified mouse anti-Ova IgG1 (BioLegend), as previously described (<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B13">13</xref>). Briefly, Ova was incubated with mouse anti-Ova IgG1 at the indicated concentrations for 30 minutes at 37&#xb0;C/5% CO<sub>2</sub>. Pre-formed Ova ICs were then added to sorted and rested ILC2s and incubated at 37&#xb0;C/5% CO<sub>2</sub> for 5 days, at which time supernatants were collected for cytokine quantification.</p>
</sec>
<sec id="s2_6">
<label>2.6</label>
<title>Cytokine quantification</title>
<p>Cytokine measurements from ILC2 supernatants were performed using the LEGENDplex&#x2122; Th Subpanel 3 Mix and Match Flow Immunoassay Kit (BioLegend), per manufacturer&#x2019;s protocol. The top standard concentration for IL-5 and IL-13 quantification are 11ng/mL and 12ng/mL, respectively.</p>
<p>For IL-33 quantification from infant lungs, upper right lungs (URL) were excised, snap-frozen in liquid nitrogen, and stored at -80&#xb0;C. For homogenization, URL was thawed on ice and homogenized in T-PER Tissue Protein Extraction Reagent (ThermoFisher) in the presence of a protease inhibitor cocktail (Promega). Homogenate was then centrifuged at 10,000rpm for removal of cellular debris. Cytokine quantification from lung homogenate was performed using the LEGENDplex&#x2122; Panel 2 Mix and Match Flow Immunoassay Kit (BioLegend), per manufacturer&#x2019;s protocol. The top standard concentration used for IL-33 quantification was 50ng/mL.</p>
<p>Samples were acquired on a Cytek Aurora configured for bead detection, per manufacturer&#x2019;s guidelines. Data was analyzed in the LEGENDplex Data Analysis Software Suite, per developer&#x2019;s instructions. A 5-parameter logistic regression curve fitting algorithm was employed to generate a best fit standard curve for each analyte, which was then used to calculate analyte concentrations in experimental samples. R<sup>2</sup> values for IL-33&#xa0;=&#xa0;0.9993; for IL-5&#xa0;=&#xa0;0.9978; and for IL-13&#xa0;=&#xa0;0.9895.</p>
</sec>
<sec id="s2_7">
<label>2.7</label>
<title>IL-33 western blot</title>
<p>Protein concentrations from URL homogenate were determined using the Bradford Assay (TCI America) according to manufacturer&#x2019;s instructions. Samples were diluted 3:1 in 4X Laemmli buffer (Biorad) with 50nM DTT and boiled for 5 minutes. 30&#x3bc;g of protein was loaded per well on a 10% TGX Fastcast Acrylamide Gel (Biorad). Gels were run at 100V for 10 minutes before voltage was increased to 150V for an additional 45 minutes. Gels were then transferred to Immobilon-PSQ PVDF Membrane (MilliporeSigma) on ice for 1 hour. Membranes were blocked in 2.5% BSA-PBS for 1 hour at room temperature and then incubated with primary antibodies targeting &#x3b2;-actin (8H10D10, Cell Signaling Technology) and IL-33 (Nessy-1; Enzo Life Sciences) diluted in 2.5% BSA-PBS overnight at 4&#xb0;C. Blots were then washed 4 times for 10 minutes in 0.1% Tween-PBS and incubated with HRP-conjugated secondary antibodies (rabbit anti-mouse IgG-HRP, Jackson Immunoresearch Laboratories; goat anti-rabbit IgG-HRP, Biorad) diluted in 2.5% non-fat milk-PBS for 1 hour at room temperature. Blots were washed as described previously and then incubated in Peirce ECL Western Blotting Substrate (Thermo Scientific) or Supersignal West Femto Maximum Sensitivity Substrate (Thermo Scientific). Blots were then imaged on a LI-COR Odyssey Imager and densitometric readings were measured using LI-COR Image Studio software (LI-COR Biosciences).</p>
</sec>
<sec id="s2_8">
<label>2.8</label>
<title>Statistical analysis</title>
<p>Statistical analyses were performed with GraphPad Prism 9 software (GraphPad Software, La Jolla, CA). Results are displayed as the mean &#xb1; SEM. For most analyses, data are compared using an unpaired t-test. Neutralizing antibody data was analyzed by nonlinear regression to obtain IC50 values, which were compared between groups using an unpaired t-test. For nonparametric ratio data, a Wilcoxon signed rank test was performed to compare the median of each group to a theoretical median of 1. For multiple comparisons, a one-way analysis of variance (ANOVA) with Tukey&#x2019;s multiple comparisons test was performed to evaluate statistical significance between groups. p values &#x2264;0.05 were considered significant.</p>
</sec>
</sec>
<sec id="s3" sec-type="results">
<label>3</label>
<title>Results</title>
<sec id="s3_1">
<label>3.1</label>
<title>ILC2s are activated in pups born to immunized dams despite complete protection from replicating RSV</title>
<p>We postulated that neutralizing maternal antibody would mitigate IL-33 production by preventing viral-mediated damage to offspring airway epithelium. To test this, offspring born to dams immunized with alum or advax adjuvanted prefusion RSV protein (mPreF) or vehicle only (mVeh) were challenged with RSV at postnatal day 7, as depicted in <xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1A</bold>
</xref>. Since mothers, not offspring, are immunized, adjuvant-mediated CD4 Th1 or Th2 skewing is not expected in offspring. Serum collected prior to viral challenge confirmed that mPreF compared to mVeh offspring had significantly higher levels of RSV neutralizing maternal antibody (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1B</bold>
</xref>). At 1 day post RSV exposure (1 dpe), lungs were harvested. As expected, mPreF offspring had undetectable RSV lung titers (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1C</bold>
</xref>) as measured by hematoxylin &amp; eosin plaque assay. Despite protection from replicating virus, levels of IL-33, an ILC2 activating cytokine, were similar between mVeh and mPreF offspring (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1D</bold>
</xref>), suggesting that prevention of RSV replication by maternal antibody failed to reduce IL-33 production.</p>
<p>We previously demonstrated that ILC2 activation peaks 4 days after secondary RSV exposure (<xref ref-type="bibr" rid="B3">3</xref>) and postulated that ILC2 activation would also occur at least 4 days after a primary RSV challenge. Thus, the study was repeated to determine if ILC2 activation was altered in mPreF vs mVeh pups at 4 dpe. Once again, RSV lung titers were undetectable in mPreF vs mVeh offspring (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1E</bold>
</xref>). Though a small increased trend was observed in ILC2 numbers from mPreF vs mVeh offspring, total numbers were similar between the groups (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1F</bold>
</xref>). The frequency of IL-13+ ILC2s were also similar between groups (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1G</bold>
</xref>). However, the proportion of IL-5+ ILC2s was markedly elevated in mPreF compared to mVeh offspring (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1H</bold>
</xref>), despite the absence of replicating virus.</p>
</sec>
<sec id="s3_2">
<label>3.2</label>
<title>ILC2s are activated following passive transfer of RSV-neutralizing antibody</title>
<p>Following RSV exposure, RSV-specific matAb binds to and neutralizes the virus resulting in the formation of immune complexes (ICs). To confirm that the ILC2 activation observed in mPreF offspring was driven by matAb:RSV ICs, ILC2 activation was measured in adult mice after passive transfer of RSV-neutralizing antibody followed by RSV challenge. Briefly heat-inactivated serum was pooled from PreF/Alum-vaccinated dams and 200&#xb5;l was intraperitoneally injected into na&#xef;ve adult mice per group 1 day prior to intranasal RSV challenge. One hour prior to sacrifice on 4 dpe, mice were intraperitoneally injected with fluorescently labeled palmitate (Bodipy C<sub>16</sub>), a fatty acid necessary for ILC2 production of IL-5 and IL-13 (<xref ref-type="bibr" rid="B6">6</xref>); lungs were processed for flow analysis of ILC2s (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2A</bold>
</xref>). Compared to unimmunized adult mice (RSV), passively immunized mice (pPreF-RSV) had a greater than 2-fold reduction in virus (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2B</bold>
</xref>). The total number of lung ILC2s trended higher in the presence of pPreF:RSV ICs (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2C</bold>
</xref>) with a parallel increasing trend in IL-13+ and IL-5+ ILC2s (<xref ref-type="fig" rid="f2">
<bold>Figures&#xa0;2D, E</bold>
</xref>). The increasing frequency of internalized Bodipy (<xref ref-type="fig" rid="f2">
<bold>Figures&#xa0;2F&#x2013;G</bold>
</xref>), further suggests an increase in fatty acid uptake to support cytokine production. These results support the findings from <xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref> that ILC2s are activated despite complete protection against RSV replication and further suggest that ILC2 activation occurs in the presence of matAb:RSV ICs. Due to the low number of mice per group, further studies are needed to confirm these results following passive delivery of RSV neutralizing antibody.</p>
</sec>
<sec id="s3_3">
<label>3.3</label>
<title>Fc&#x3b3;Rs are expressed on murine and human airway ILC2s</title>
<p>IL-5+ ILC2s were increased in mPreF vs mVeh offspring despite similar levels of IL-33, suggesting an alternative mechanism of ILC2 activation. Fc&#x3b3;R expression has been detected on other members of the ILC family of innate cells (NK cells and ILC3s) but has not been reported on lung ILC2s (<xref ref-type="bibr" rid="B14">14</xref>&#x2013;<xref ref-type="bibr" rid="B16">16</xref>). Thus, we investigated the expression of Fc gamma receptors (Fc&#x3b3;R) on pulmonary ILC2s as a possible mechanism by which matAb:RSV ICs mediate ILC2 activation (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3</bold>
</xref>). Fluorescence minus one (FMOs) controls were used to identify positive Fc&#x3b3;R staining (<xref ref-type="fig" rid="f3">
<bold>Figures&#xa0;3A, D</bold>
</xref>). Expression of activating (Fc&#x3b3;RIII; <xref ref-type="fig" rid="f3">
<bold>Figures&#xa0;3A&#x2013;C</bold>
</xref>) and inhibitory (Fc&#x3b3;RIIb; <xref ref-type="fig" rid="f3">
<bold>Figures&#xa0;3D&#x2013;F</bold>
</xref>) Fc&#x3b3;Rs was detected on the surface of murine lung ILC2s. In mPreF offspring, the presence of matAb : RSV ICs was associated with a significant reduction in the frequency of ILC2s expressing Fc&#x3b3;RIII and Fc&#x3b3;RIIb compared to mVeh offspring (<xref ref-type="fig" rid="f3">
<bold>Figures&#xa0;3G&#x2013;H</bold>
</xref>). Reduced expression suggests internalization of IC-bound Fc&#x3b3;R following ligation by matAb : RSV ICs and is consistent with ligation-mediated Fc&#x3b3;R internalization described in other innate cells (<xref ref-type="bibr" rid="B17">17</xref>&#x2013;<xref ref-type="bibr" rid="B19">19</xref>). The strength of Fc&#x3b3;R responses is largely determined by the ratio of activating to inhibitory receptors (<xref ref-type="bibr" rid="B20">20</xref>). Importantly, the ratio of activating Fc&#x3b3;RIII to inhibitory Fc&#x3b3;RIIb expression was markedly reduced in mPreF vs. mVeh offspring, suggesting greater internalization of activating Fc&#x3b3;RIII (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3J</bold>
</xref>). Fc&#x3b3;RI expression was not altered by matAb:RSV ICs (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3I</bold>
</xref>), aligning with reports that Fc&#x3b3;RI does not bind IgG1, the predominant isotype generated following vaccination with Alum adjuvant (<xref ref-type="bibr" rid="B21">21</xref>). Because, Fc&#x3b3;R expression differs between mice and humans (<xref ref-type="bibr" rid="B22">22</xref>), we asked if Fc&#x3b3;Rs are expressed on human ILC2s. ILC2s harvested from the lavage fluid of pediatric patients undergoing adenoidectomies expressed low levels of activating Fc&#x3b3;RIII and high levels of inhibitory Fc&#x3b3;RII (<xref ref-type="fig" rid="f3">
<bold>Figures&#xa0;3K&#x2013;N</bold>
</xref>), suggesting a functional role for Fc&#x3b3;R on human ILC2s. Together this data describes the first known report of activating and inhibitory Fc&#x3b3;R expression on murine and human ILC2s and suggests a potential alternative mechanism of ILC2 activation following ligation and internalization of Fc&#x3b3;RIII by matAb:RSV ICs.</p>
</sec>
<sec id="s3_4">
<label>3.4</label>
<title>Ex vivo stimulation with Ab:RSV ICs attenuates IL-33-mediated ILC2 activation</title>
<p>To determine if ILC2s are capable of Fc&#x3b3;R-mediated activation by Ab : RSV ICs, purified ILC2s were cultured with pre-formed Ab : RSV ICs and cytokine responses were measured. Briefly, na&#xef;ve lungs were digested and processed for FACS sorting according to published protocols (<xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B24">24</xref>). Purified ILC2s, defined as Live, CD45<sup>+</sup>, Lin<sup>-</sup>, CD49b<sup>-</sup> CD117<sup>-</sup> CD127<sup>+</sup> ST2<sup>+</sup>, were then seeded into 96-well plates at a density of 5,000 cells/well and rested overnight (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4A</bold>
</xref>). One hour prior to stimulation, Ab : RSV ICs were generated by incubating heat-inactivated serum from DS-Cav1/PreF-vaccinated dams with RSV L19 at a serum dilution (1:10) and viral dose (2.5x10<sup>4</sup> PFUs) optimized to neutralize RSV replication. ILC2s were left untreated or stimulated with IL-33 and/or Ab:RSV ICs and supernatants were collected for cytokine quantification at 5-days post-stimulation (dps; <xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4B</bold>
</xref>). As expected, IL-33 stimulation of ILC2s induced production of IL-5 and IL-13 (<xref ref-type="fig" rid="f4">
<bold>Figures&#xa0;4C, D</bold>
</xref>). Surprisingly, Ab:RSV ICs not only failed to induce IL-5 and IL-13 production, they significantly attenuated IL-33-induced IL-5 and IL-13 production (<xref ref-type="fig" rid="f4">
<bold>Figures&#xa0;4C, D</bold>
</xref>).</p>
<fig id="f4" position="float">
<label>Figure&#xa0;4</label>
<caption>
<p>Ex vivo stimulation with Ab : RSV ICs attenuates IL-33-mediated ILC2 activation. ILC2s, defined as live, CD45<sup>+</sup>, Lin<sup>-</sup>, CD49b<sup>-</sup> CD117<sup>-</sup> CD127<sup>+</sup> ST2<sup>+</sup>, were sorted from the lungs of naive adult mice and seeded into 96-well plates <bold>(A)</bold>. Cells were left untreated or stimulated with pre-formed Ab:RSV ICs +/- IL-33 (10ng/mL) <bold>(B)</bold>. At 5dps, IL-5 <bold>(C)</bold> and IL-13 <bold>(D)</bold> were quantified from ILC2 supernatants. In a repeat experiment, cells were left untreated or stimulated with 10ng/mL of IL-33 or increasing concentrations of pre-formed Ova ICs at the following ratios of Ova (mg/mL) to Anti-Ova IgG1 (mg/mL): Ova IC [A] 32.5/22.5, Ova IC [B] 65/45, Ova IC [C] 97.5/67.5, Ova IC [D] 130/90, Ova IC [E] 195/135, Ova IC [F] 260/180 <bold>(E)</bold>. At 5dps, IL-5 <bold>(F)</bold> and IL-13 <bold>(G)</bold> were quantified from ILC2 supernatants. In a third ex vivo experiment, cells were left untreated or stimulated with IL-33 alone or in combination with increasing concentrations of pre-formed Ova ICs at the following ratios of Ova (mg/mL) to A-Ova IgG1 (mg/mL): Ova IC [B] 65/45, Ova IC [C] 97.5/67.5, and Ova IC [D] 130/90 <bold>(H)</bold>. At 5dps, IL-5 <bold>(I)</bold> and IL-13 <bold>(J)</bold> were quantified from ILC2 supernatants. Dotted line represents the minimal detectable concentration. Data are represented as mean &#xb1; SEM (n=3-5 samples per group). Statistical significance was calculated using a one-way ANOVA with Tukey&#x2019;s multiple comparison post-test. *p &#x2264; 0.05, **p &#x2264; 0.01, and ***p &#x2264; 0.01, ****p &#x2264; 0.0001. Created with <uri xlink:href="https://BioRender.com">BioRender.com</uri>.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1374818-g004.tif"/>
</fig>
</sec>
<sec id="s3_5">
<label>3.5</label>
<title>Increasing concentrations of Ova ICs fail to activate ILC2s</title>
<p>In mice, Fc&#x3b3;RIIb has higher affinity for IgG1 than Fc&#x3b3;RIII and at low concentrations, ICs comprised of IgG1 preferentially bind Fc&#x3b3;RIIb and inhibit cell activation (<xref ref-type="bibr" rid="B25">25</xref>&#x2013;<xref ref-type="bibr" rid="B27">27</xref>). As the concentration of ICs increase, so too does their engagement of the lower affinity activating Fc&#x3b3;R, Fc&#x3b3;RIII, ultimately shifting cellular responses (<xref ref-type="bibr" rid="B25">25</xref>). To test whether activation via Fc&#x3b3;RIII was concentration dependent, cytokine production was quantified from purified ILC2s &#x2013; as described in <xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4A</bold>
</xref> <bold>&#x2013;</bold> and stimulated with increasing concentrations of Ova ICs (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4E</bold>
</xref>). Ova ICs were selected because, unlike RSV Ab ICs, the ratio of Ab to Ag could be controlled more precisely. Moreover, Ova ICs elicit cytokine production from Fc&#x3b3;RII- and Fc&#x3b3;RIII-expressing mast cells (<xref ref-type="bibr" rid="B28">28</xref>, <xref ref-type="bibr" rid="B29">29</xref>), which, similar to ILC2s, orchestrate non-specific type 2 inflammation, including IL-13 production (<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B30">30</xref>). Ova ICs of various concentrations were generated by incubating known concentrations of anti-Ova IgG1 antibody and Ova antigen, such that the molar antibody:antigen ratio remained constant. The pre-formed Ova ICs were then added to rested ILC2s and supernatants were collected at 5dps for cytokine quantification. As expected, ILC2s exposed to IL-33 (positive control) elicited high levels of IL-5 and IL-13 (<xref ref-type="fig" rid="f4">
<bold>Figures&#xa0;4F&#x2013;G</bold>
</xref>). However, high concentrations of Ova ICs failed to elicit detectable quantities of either cytokine (<xref ref-type="fig" rid="f4">
<bold>Figures&#xa0;4F&#x2013;G</bold>
</xref>), suggesting that IgG1 ICs alone, even at higher concentrations, are not capable of activating ILC2s directly.</p>
<p>In the lungs of mPreF pups, IL-33 is present in similar quantities as those found in mVeh pups (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1D</bold>
</xref>). Thus, we postulated that Ova ICs may combine with IL-33 to enhance ILC2 cytokine production. To test this hypothesis, purified ILC2s were stimulated with IL-33 in the presence of 3 increasing Ova IC concentrations described in <xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4H</bold>
</xref>; cytokine levels were quantified at 5dps. Concentrations in the middle of the range [B-D], instead of the higher range [E-F] were chosen to improve our chances of seeing a dose-response when combined with IL-33. Similar to Ab:RSV ICs, high concentrations of Ova ICs reduced IL-5 and IL-13 production elicited by IL-33 alone (<xref ref-type="fig" rid="f4">
<bold>Figures&#xa0;4I&#x2013;J</bold>
</xref>).</p>
</sec>
</sec>
<sec id="s4" sec-type="discussion">
<label>4</label>
<title>Discussion</title>
<p>The current understanding of ILC2 activation during RSV infection, is that ILC2s are activated by alarmins, including IL-33, released from airway epithelial cells in response to viral-mediated damage (<xref ref-type="bibr" rid="B31">31</xref>). Thus, high levels of RSV neutralizing matAb, would be expected to mitigate ILC2 activation (<xref ref-type="bibr" rid="B32">32</xref>). With similar IL-33 levels in mPreF vs mVeh pups, our novel discovery of Fc&#x3b3;R expression on ILC2s poses a promising alternative mechanism of ILC2 activation in the absence of overt lung damage. It is important to note that the frequency of IL-5, but not IL-13, was increased in mPreF vs mVeh offspring (<xref ref-type="fig" rid="f1">
<bold>Figures&#xa0;1G, H</bold>
</xref>) and while both cytokines consistently trended up in adults treated with ICs, significance was not achieved due to low animal numbers (<xref ref-type="fig" rid="f2">
<bold>Figures&#xa0;2D, E</bold>
</xref>). Nonetheless, our ex vivo stimulation assay designed to interrogate Fc&#x3b3;R function on ILC2s was unable to replicate the <italic>in vivo</italic> findings, and in fact, showed a suppression of IL-33-mediated ILC2 activation. A possible explanation for this discrepancy may be the amount of maternal antibody present <italic>in vivo</italic> vs ex vivo. While the titer of neutralizing maternal antibody present in infant mice at the time of RSV exposure is known, the quantity of matAb : RSV ICs is not known. Use of anti-Ova IgG1 was an approach to control the IC concentration used for ex vivo stimulation. However, the differences between the diverse population of antibodies generated during maternal immunization and that of the monoclonal anti-Ova antibody are extensive. For example, though both antibody pools are of the IgG1 subclass, the glycosylation patterns between the anti-DS-Cav1 antibody repertoire generated during maternal immunization and those of the monoclonal anti-Ova antibody are likely to differ tremendously (<xref ref-type="bibr" rid="B33">33</xref>). N-linked glycosylation is the most common post-transcriptional modification that functionally impacts IgG1 and can be altered by multiple factors, including sex, infection, and pregnancy (<xref ref-type="bibr" rid="B34">34</xref>). Additionally, the antibody:antigen ratio and size of ICs, which differs greatly between protein antigens (i.e. Ova vs DS-Cav1), impacts their mechanism of detection, extent of Fc&#x3b3;R crosslinking, and downstream cellular responses (<xref ref-type="bibr" rid="B35">35</xref>&#x2013;<xref ref-type="bibr" rid="B37">37</xref>). These factors complicate the translation of our <italic>in vivo</italic> findings to an ex vivo assay and may explain the failure of increasing Ova IC concentrations to stimulate ILC2s ex vivo. Future work will quantify matAb : RSV ICs present in the airways of mPreF pups to guide the generation of comparable quantities of ICs for ex vivo stimulation. Generation of ICs using anti-DS-Cav1 antibodies purified from the serum of directly vaccinated dams would also better mimic the antibody repertoire in mPreF pups and improve the interrogation of Fc&#x3b3;R-mediated ILC2 activation. In addition to IL-33, other ILC2 activators (ex. TSLP, IL-25, PGD2) will be considered in future studies.</p>
<p>The complement system is a critical component of innate defense against pathogens and is rapidly initiated following detection of ICs (<xref ref-type="bibr" rid="B38">38</xref>). Specifically, when complement-fixing Abs, like IgG1 attach to viral surfaces, a cascade of events result in the conversion of C3 to C3a (<xref ref-type="bibr" rid="B39">39</xref>). In neonatal mice, the baseline concentration of C3 is markedly lower compared to adults and their ability to increase C3/C3a concentrations in response to IC detection is comparatively stunted (<xref ref-type="bibr" rid="B40">40</xref>). Interestingly, C3a is a mediator shown to directly activate ILC2s via ligation of C3aR (<xref ref-type="bibr" rid="B41">41</xref>). Because neonatal mice have reduced complement activity, our ex vivo stimulation assay used heat-inactivated serum to better mimic the neonatal environment demonstrated to foster ILC2 activation in the presence of matAb : RSV ICs (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4B</bold>
</xref>). However, the complete absence of complement may also explain the failure of ICs to stimulate ILC2s ex vivo. Future ex vivo stimulation assays will assess ILC2 activation in cultures containing low C3 concentrations and interrogate signaling events associated with C3aR ligation.</p>
<p>It is possible that cytokine production from ILC2s is not directly elicited by matAb:RSV ICs, but instead by cellular mediators elicited following IC-mediated activation of other immune cell populations. In support of this hypothesis is preliminary data in our model showing higher levels of cleaved IL-33 in mPreF vs. mVeh pups (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figures S1A, B</bold>
</xref>). Cleavage of full-length IL-33 into its more biologically potent form is mediated by inflammatory proteases produced by neutrophils and mast cells (<xref ref-type="bibr" rid="B42">42</xref>&#x2013;<xref ref-type="bibr" rid="B44">44</xref>). The increase in cleaved IL-33 in mPreF pups suggests that matAb:RSV ICs drive early cellular responses not captured in our current studies that are responsible for neutrophil or mast cell activation and the subsequent proteolytic cleavage of IL-33. In fact, presence of ICs in the airways can lead to acute lung injury and subsequent complement-dependent neutrophil recruitment to the airways (<xref ref-type="bibr" rid="B45">45</xref>). Therefore, it is intriguing to hypothesize that matAb:RSV IC-mediated acute lung damage leads to the rapid influx of neutrophils providing the proteases necessary to generate cleaved IL-33 and activate ILC2s.</p>
<p>Fc&#x3b3;R ligation on ILC2s may have alternative functions, such as mediating internalization of exogenous antigens (<xref ref-type="bibr" rid="B46">46</xref>). In addition to their cytokine producing effector cells, ILC2s are also capable of antigen presentation and CD4<sup>+</sup> T cell activation (<xref ref-type="bibr" rid="B47">47</xref>&#x2013;<xref ref-type="bibr" rid="B49">49</xref>). On traditional antigen presenting cells, ICs bind Fc&#x3b3;Rs, triggering their internalization and delivery to lysosomes, where they are processed and loaded into MHCII molecules for cell-surface presentation and CD4<sup>+</sup> T cell priming/activation (<xref ref-type="bibr" rid="B50">50</xref>). In infants born to maternally vaccinated dams, the frequency of MHCII<sup>+</sup> ILC2s is significantly higher in mPreF vs mVeh pups, providing compelling preliminary evidence for the antigen presentation function of Fc&#x3b3;Rs on ILC2s (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figure S1C</bold>
</xref>).</p>
<p>Collectively, this brief report describes changes in ILC2 activation and Fc&#x3b3;R expression in the presence of neutralizing matAb that occur despite complete protection against RSV replication. To our knowledge, this is the first report of Fc&#x3b3;R expression on lung ILC2s with differential expression in the presence of matAb. These data warrant further studies to better understand how ILC2s are differentially regulated in the presence of RSV-neutralizing maternal antibody despite protection against replicating virus. Understanding how matAb alters the infant immune response to virus is particularly important to minimize unwanted type 2 inflammation in early-life and ensure the long-term safety of maternal RSV vaccines.</p>
</sec>
<sec id="s5" sec-type="data-availability">
<title>Data availability statement</title>
<p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p>
</sec>
<sec id="s6" sec-type="ethics-statement">
<title>Ethics statement</title>
<p>The studies involving humans were approved by University of Pittsburgh Institutional Review Board. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation in this study was provided by the participants&#x2019; legal guardians/next of kin. The animal study was approved by University of Pittsburgh Institutional Animal Care and Use Committee. The study was conducted in accordance with the local legislation and institutional requirements.</p>
</sec>
<sec id="s7" sec-type="author-contributions">
<title>Author contributions</title>
<p>JK: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. KEi: Data curation, Investigation, Writing &#x2013; review &amp; editing. ML: Investigation, Methodology, Writing &#x2013; review &amp; editing. SG: Methodology, Writing &#x2013; review &amp; editing. DB: Methodology, Writing &#x2013; review &amp; editing. MY: Methodology, Writing &#x2013; review &amp; editing. DC: Resources, Writing &#x2013; review &amp; editing. TP: Formal analysis, Writing &#x2013; review &amp; editing. KEm: Conceptualization, Funding acquisition, Project administration, Resources, Supervision, Visualization, Writing &#x2013; review &amp; editing.</p>
</sec>
</body>
<back>
<sec id="s8" sec-type="funding-information">
<title>Funding</title>
<p>The author(s) declare financial support was received for the research, authorship, and/or publication of this article. Financial support was provided by: 1R43AI140941-01 (PI : MY/KEm), R21AI171241 (KEm/Meng); David and Betty Brenneman Fund (KEm), R03-RHD080874A (PI: KEm), and the Center for Clinical Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy all contributed to the resources and support for this work. This work benefited from SPECIAL BD LSRFORTESSATM funded by NIH 1S10OD011925-01 (PI : Borghesi).</p>
</sec>
<sec id="s9" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>SG, DB, and MY are employed by Calder Biosciences Inc.</p>
<p>The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s10" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s11" sec-type="disclaimer">
<title>Author disclaimer</title>
<p>This publication&#x2019;s contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health, National Institute of Allergy and Infectious Diseases.</p>
</sec>
<sec id="s12" sec-type="supplementary-material">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fimmu.2024.1374818/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fimmu.2024.1374818/full#supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="Presentation_1.pptx" id="SM1" mimetype="application/vnd.openxmlformats-officedocument.presentationml.presentation"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schneider</surname> <given-names>C</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>J</given-names>
</name>
<name>
<surname>Koga</surname> <given-names>S</given-names>
</name>
<name>
<surname>Ricardo-Gonzalez</surname> <given-names>RR</given-names>
</name>
<name>
<surname>Nussbaum</surname> <given-names>JC</given-names>
</name>
<name>
<surname>Smith</surname> <given-names>LK</given-names>
</name>
<etal/>
</person-group>. <article-title>Tissue-resident group 2 innate lymphoid cells differentiate by layered ontogeny and <italic>in situ</italic> perinatal priming</article-title>. <source>Immunity</source>. (<year>2019</year>) <volume>50</volume>:<fpage>1425</fpage>&#x2013;<lpage>38 e5</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.immuni.2019.04.019</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steer</surname> <given-names>CA</given-names>
</name>
<name>
<surname>Matha</surname> <given-names>L</given-names>
</name>
<name>
<surname>Shim</surname> <given-names>H</given-names>
</name>
<name>
<surname>Takei</surname> <given-names>F</given-names>
</name>
</person-group>. <article-title>Lung group 2 innate lymphoid cells are trained by endogenous IL-33 in the neonatal period</article-title>. <source>JCI Insight</source>. (<year>2020</year>) <volume>5</volume>:<elocation-id>e135961</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1172/jci.insight.135961</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kosanovich</surname> <given-names>JL</given-names>
</name>
<name>
<surname>Eichinger</surname> <given-names>KM</given-names>
</name>
<name>
<surname>Lipp</surname> <given-names>MA</given-names>
</name>
<name>
<surname>Gidwani</surname> <given-names>SV</given-names>
</name>
<name>
<surname>Brahmbhatt</surname> <given-names>D</given-names>
</name>
<name>
<surname>Yondola</surname> <given-names>MA</given-names>
</name>
<etal/>
</person-group>. <article-title>Exacerbated lung inflammation following secondary RSV exposure is CD4+ T cell-dependent and is not mitigated in infant BALB/c mice born to PreF-vaccinated dams</article-title>. <source>Front Immunol</source>. (<year>2023</year>) <volume>14</volume>:<elocation-id>1206026</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2023.1206026</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Empey</surname> <given-names>KM</given-names>
</name>
<name>
<surname>Orend</surname> <given-names>JG</given-names>
</name>
<name>
<surname>Peebles</surname> <given-names>RS</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>Egana</surname> <given-names>L</given-names>
</name>
<name>
<surname>Norris</surname> <given-names>KA</given-names>
</name>
<name>
<surname>Oury</surname> <given-names>TD</given-names>
</name>
<etal/>
</person-group>. <article-title>Stimulation of immature lung macrophages with intranasal interferon gamma in a novel neonatal mouse model of respiratory syncytial virus infection</article-title>. <source>PloS One</source>. (<year>2012</year>) <volume>7</volume>:<elocation-id>e40499</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pone.0040499</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Graham</surname> <given-names>BS</given-names>
</name>
<name>
<surname>Perkins</surname> <given-names>MD</given-names>
</name>
<name>
<surname>Wright</surname> <given-names>PF</given-names>
</name>
<name>
<surname>Karzon</surname> <given-names>DT</given-names>
</name>
</person-group>. <article-title>Primary respiratory syncytial virus infection in mice</article-title>. <source>J Med Virol</source>. (<year>1988</year>) <volume>26</volume>:<page-range>153&#x2013;62</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/jmv.1890260207</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilhelm</surname> <given-names>C</given-names>
</name>
<name>
<surname>Harrison</surname> <given-names>OJ</given-names>
</name>
<name>
<surname>Schmitt</surname> <given-names>V</given-names>
</name>
<name>
<surname>Pelletier</surname> <given-names>M</given-names>
</name>
<name>
<surname>Spencer</surname> <given-names>SP</given-names>
</name>
<name>
<surname>Urban</surname> <given-names>JF</given-names>
<suffix>Jr.</suffix>
</name>
<etal/>
</person-group>. <article-title>Critical role of fatty acid metabolism in ILC2-mediated barrier protection during malnutrition and helminth infection</article-title>. <source>J Exp Med</source>. (<year>2016</year>) <volume>213</volume>:<page-range>1409&#x2013;18</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1084/jem.20151448</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eichinger</surname> <given-names>KM</given-names>
</name>
<name>
<surname>Kosanovich</surname> <given-names>JL</given-names>
</name>
<name>
<surname>Gidwani</surname> <given-names>SV</given-names>
</name>
<name>
<surname>Zomback</surname> <given-names>A</given-names>
</name>
<name>
<surname>Lipp</surname> <given-names>MA</given-names>
</name>
<name>
<surname>Perkins</surname> <given-names>TN</given-names>
</name>
<etal/>
</person-group>. <article-title>Prefusion RSV F immunization elicits th2-mediated lung pathology in mice when formulated with a th2 (but not a th1/th2-balanced) adjuvant despite complete viral protection</article-title>. <source>Front Immunol</source>. (<year>2020</year>) <volume>11</volume>:<elocation-id>1673</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2020.01673</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eichinger</surname> <given-names>KM</given-names>
</name>
<name>
<surname>Kosanovich</surname> <given-names>JL</given-names>
</name>
<name>
<surname>Lipp</surname> <given-names>MA</given-names>
</name>
<name>
<surname>Perkins</surname> <given-names>TN</given-names>
</name>
<name>
<surname>Petrovsky</surname> <given-names>N</given-names>
</name>
<name>
<surname>Marshall</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Maternal immunization with adjuvanted RSV prefusion F protein effectively protects offspring from RSV challenge and alters innate and T cell immunity</article-title>. <source>Vaccine</source>. (<year>2020</year>) <volume>38</volume>:<page-range>7885&#x2013;91</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.vaccine.2020.10.065</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eichinger</surname> <given-names>KM</given-names>
</name>
<name>
<surname>Kosanovich</surname> <given-names>JL</given-names>
</name>
<name>
<surname>Perkins</surname> <given-names>TN</given-names>
</name>
<name>
<surname>Oury</surname> <given-names>TD</given-names>
</name>
<name>
<surname>Petrovsky</surname> <given-names>N</given-names>
</name>
<name>
<surname>Marshall</surname> <given-names>CP</given-names>
</name>
<etal/>
</person-group>. <article-title>Prior respiratory syncytial virus infection reduces vaccine-mediated Th2-skewed immunity, but retains enhanced RSV F-specific CD8 T cell responses elicited by a Th1-skewing vaccine formulation</article-title>. <source>Front Immunol</source>. (<year>2022</year>) <volume>13</volume>:<elocation-id>1025341</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2022.1025341</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kosanovich</surname> <given-names>JL</given-names>
</name>
<name>
<surname>Eichinger</surname> <given-names>KM</given-names>
</name>
<name>
<surname>Lipp</surname> <given-names>MA</given-names>
</name>
<name>
<surname>Yondola</surname> <given-names>MA</given-names>
</name>
<name>
<surname>Perkins</surname> <given-names>TN</given-names>
</name>
<name>
<surname>Empey</surname> <given-names>KM</given-names>
</name>
</person-group>. <article-title>Formulation of the prefusion RSV F protein with a Th1/Th2-balanced adjuvant provides complete protection without Th2-skewed immunity in RSV-experienced young mice</article-title>. <source>Vaccine</source>. (<year>2020</year>) <volume>38</volume>:<page-range>6357&#x2013;62</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.vaccine.2020.08.023</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eichinger</surname> <given-names>KM</given-names>
</name>
<name>
<surname>Kosanovich</surname> <given-names>JL</given-names>
</name>
<name>
<surname>Empey</surname> <given-names>KM</given-names>
</name>
</person-group>. <article-title>Localization of the T-cell response to RSV infection is altered in infant mice</article-title>. <source>Pediatr Pulmonol</source>. (<year>2018</year>) <volume>53</volume>:<page-range>145&#x2013;53</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/ppul.23911</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Larsson</surname> <given-names>L</given-names>
</name>
<name>
<surname>Bruhns</surname> <given-names>P</given-names>
</name>
<name>
<surname>Xiang</surname> <given-names>Z</given-names>
</name>
</person-group>. <article-title>Apoptosis of mouse mast cells is reciprocally regulated by the IgG receptors FcgammaRIIB and FcgammaRIIIA</article-title>. <source>Allergy</source>. (<year>2012</year>) <volume>67</volume>:<page-range>1233&#x2013;40</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/j.1398-9995.2012.02878.x.</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ding</surname> <given-names>J</given-names>
</name>
<name>
<surname>Fang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Xiang</surname> <given-names>Z</given-names>
</name>
</person-group>. <article-title>Antigen/IgG immune complex-primed mucosal mast cells mediate antigen-specific activation of co-cultured T cells</article-title>. <source>Immunology</source>. (<year>2015</year>) <volume>144</volume>:<page-range>387&#x2013;94</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/imm.12379</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prehn</surname> <given-names>JL</given-names>
</name>
<name>
<surname>Thomas</surname> <given-names>LS</given-names>
</name>
<name>
<surname>Landers</surname> <given-names>CJ</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>QT</given-names>
</name>
<name>
<surname>Michelsen</surname> <given-names>KS</given-names>
</name>
<name>
<surname>Targan</surname> <given-names>SR</given-names>
</name>
</person-group>. <article-title>The T cell costimulator TL1A is induced by FcgammaR signaling in human monocytes and dendritic cells</article-title>. <source>J Immunol</source>. (<year>2007</year>) <volume>178</volume>:<page-range>4033&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4049/jimmunol.178.7.4033</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uo</surname> <given-names>M</given-names>
</name>
<name>
<surname>Hisamatsu</surname> <given-names>T</given-names>
</name>
<name>
<surname>Miyoshi</surname> <given-names>J</given-names>
</name>
<name>
<surname>Kaito</surname> <given-names>D</given-names>
</name>
<name>
<surname>Yoneno</surname> <given-names>K</given-names>
</name>
<name>
<surname>Kitazume</surname> <given-names>MT</given-names>
</name>
<etal/>
</person-group>. <article-title>Mucosal CXCR4+ IgG plasma cells contribute to the pathogenesis of human ulcerative colitis through FcgammaR-mediated CD14 macrophage activation</article-title>. <source>Gut</source>. (<year>2013</year>) <volume>62</volume>:<page-range>1734&#x2013;44</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1136/gutjnl-2012-303063</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koues</surname> <given-names>OI</given-names>
</name>
<name>
<surname>Collins</surname> <given-names>PL</given-names>
</name>
<name>
<surname>Cella</surname> <given-names>M</given-names>
</name>
<name>
<surname>Robinette</surname> <given-names>ML</given-names>
</name>
<name>
<surname>Porter</surname> <given-names>SI</given-names>
</name>
<name>
<surname>Pyfrom</surname> <given-names>SC</given-names>
</name>
<etal/>
</person-group>. <article-title>Distinct gene regulatory pathways for human innate versus adaptive lymphoid cells</article-title>. <source>Cell</source>. (<year>2016</year>) <volume>165</volume>:<page-range>1134&#x2013;46</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cell.2016.04.014</pub-id>
</citation>
</ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mellman</surname> <given-names>IS</given-names>
</name>
<name>
<surname>Plutner</surname> <given-names>H</given-names>
</name>
<name>
<surname>Steinman</surname> <given-names>RM</given-names>
</name>
<name>
<surname>Unkeless</surname> <given-names>JC</given-names>
</name>
<name>
<surname>Cohn</surname> <given-names>ZA</given-names>
</name>
</person-group>. <article-title>Internalization and degradation of macrophage Fc receptors during receptor-mediated phagocytosis</article-title>. <source>J Cell Biol</source>. (<year>1983</year>) <volume>96</volume>:<page-range>887&#x2013;95</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1083/jcb.96.3.887</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mellman</surname> <given-names>I</given-names>
</name>
<name>
<surname>Plutner</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>Internalization and degradation of macrophage Fc receptors bound to polyvalent immune complexes</article-title>. <source>J Cell Biol</source>. (<year>1984</year>) <volume>98</volume>:<page-range>1170&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1083/jcb.98.4.1170</pub-id>
</citation>
</ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khodoun</surname> <given-names>MV</given-names>
</name>
<name>
<surname>Kucuk</surname> <given-names>ZY</given-names>
</name>
<name>
<surname>Strait</surname> <given-names>RT</given-names>
</name>
<name>
<surname>Krishnamurthy</surname> <given-names>D</given-names>
</name>
<name>
<surname>Janek</surname> <given-names>K</given-names>
</name>
<name>
<surname>Clay</surname> <given-names>CD</given-names>
</name>
<etal/>
</person-group>. <article-title>Rapid desensitization of mice with anti-FcgammaRIIb/FcgammaRIII mAb safely prevents IgG-mediated anaphylaxis</article-title>. <source>J Allergy Clin Immunol</source>. (<year>2013</year>) <volume>132</volume>:<page-range>1375&#x2013;87</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jaci.2013.09.008</pub-id>
</citation>
</ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clynes</surname> <given-names>RA</given-names>
</name>
<name>
<surname>Towers</surname> <given-names>TL</given-names>
</name>
<name>
<surname>Presta</surname> <given-names>LG</given-names>
</name>
<name>
<surname>Ravetch</surname> <given-names>JV</given-names>
</name>
</person-group>. <article-title>Inhibitory Fc receptors modulate in <italic>vivo</italic> cytotoxicity against tumor targets</article-title>. <source>Nat Med</source>. (<year>2000</year>) <volume>6</volume>:<page-range>443&#x2013;6</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/74704</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kool</surname> <given-names>M</given-names>
</name>
<name>
<surname>Soullie</surname> <given-names>T</given-names>
</name>
<name>
<surname>van Nimwegen</surname> <given-names>M</given-names>
</name>
<name>
<surname>Willart</surname> <given-names>MA</given-names>
</name>
<name>
<surname>Muskens</surname> <given-names>F</given-names>
</name>
<name>
<surname>Jung</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells</article-title>. <source>J Exp Med</source>. (<year>2008</year>) <volume>205</volume>:<page-range>869&#x2013;82</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1084/jem.20071087</pub-id>
</citation>
</ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zoler</surname> <given-names>ML</given-names>
</name>
</person-group>. <article-title>Immune complexes initiate RSV pathology</article-title>. <source>JAMA</source>. (<year>1983</year>) <volume>249</volume>:<page-range>447, 51&#x2013;2</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1001/jama.1983.03330280005004</pub-id>
</citation>
</ref>
<ref id="B23">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Silver</surname> <given-names>J</given-names>
</name>
<name>
<surname>Humbles</surname> <given-names>AA</given-names>
</name>
<name>
<surname>Ohne</surname> <given-names>Y</given-names>
</name>
</person-group>. <article-title>Isolation, culture, and induction of plasticity in ILC2s</article-title>. <source>Methods Mol Biol</source>. (<year>2020</year>) <volume>2121</volume>:<page-range>115&#x2013;27</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/978-1-0716-0338-3_11</pub-id>
</citation>
</ref>
<ref id="B24">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moro</surname> <given-names>K</given-names>
</name>
<name>
<surname>Kabata</surname> <given-names>H</given-names>
</name>
<name>
<surname>Tanabe</surname> <given-names>M</given-names>
</name>
<name>
<surname>Koga</surname> <given-names>S</given-names>
</name>
<name>
<surname>Takeno</surname> <given-names>N</given-names>
</name>
<name>
<surname>Mochizuki</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Interferon and IL-27 antagonize the function of group 2 innate lymphoid cells and type 2 innate immune responses</article-title>. <source>Nat Immunol</source>. (<year>2016</year>) <volume>17</volume>:<fpage>76</fpage>&#x2013;<lpage>86</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/ni.3309</pub-id>
</citation>
</ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nimmerjahn</surname> <given-names>F</given-names>
</name>
<name>
<surname>Ravetch</surname> <given-names>JV</given-names>
</name>
</person-group>. <article-title>Fcgamma receptors: old friends and new family members</article-title>. <source>Immunity</source>. (<year>2006</year>) <volume>24</volume>:<fpage>19</fpage>&#x2013;<lpage>28</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.immuni.2005.11.010</pub-id>
</citation>
</ref>
<ref id="B26">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karsten</surname> <given-names>CM</given-names>
</name>
<name>
<surname>Pandey</surname> <given-names>MK</given-names>
</name>
<name>
<surname>Figge</surname> <given-names>J</given-names>
</name>
<name>
<surname>Kilchenstein</surname> <given-names>R</given-names>
</name>
<name>
<surname>Taylor</surname> <given-names>PR</given-names>
</name>
<name>
<surname>Rosas</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcgammaRIIB and dectin-1</article-title>. <source>Nat Med</source>. (<year>2012</year>) <volume>18</volume>:<page-range>1401&#x2013;6</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nm.2862</pub-id>
</citation>
</ref>
<ref id="B27">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Verbeek</surname> <given-names>JS</given-names>
</name>
<name>
<surname>Hirose</surname> <given-names>S</given-names>
</name>
<name>
<surname>Nishimura</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>The complex association of fcgammaRIIb with autoimmune susceptibility</article-title>. <source>Front Immunol</source>. (<year>2019</year>) <volume>10</volume>:<elocation-id>2061</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2019.02061</pub-id>
</citation>
</ref>
<ref id="B28">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Katz</surname> <given-names>HR</given-names>
</name>
<name>
<surname>Raizman</surname> <given-names>MB</given-names>
</name>
<name>
<surname>Gartner</surname> <given-names>CS</given-names>
</name>
<name>
<surname>Scott</surname> <given-names>HC</given-names>
</name>
<name>
<surname>Benson</surname> <given-names>AC</given-names>
</name>
<name>
<surname>Austen</surname> <given-names>KF</given-names>
</name>
</person-group>. <article-title>Secretory granule mediator release and generation of oxidative metabolites of arachidonic acid <italic>via</italic> Fc-IgG receptor bridging in mouse mast cells</article-title>. <source>J Immunol</source>. (<year>1992</year>) <volume>148</volume>:<page-range>868&#x2013;71</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4049/jimmunol.148.3.868</pub-id>
</citation>
</ref>
<ref id="B29">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Katz</surname> <given-names>HR</given-names>
</name>
<name>
<surname>Arm</surname> <given-names>JP</given-names>
</name>
<name>
<surname>Benson</surname> <given-names>AC</given-names>
</name>
<name>
<surname>Austen</surname> <given-names>KF</given-names>
</name>
</person-group>. <article-title>Maturation-related changes in the expression of Fc gamma RII and Fc gamma RIII on mouse mast cells derived in <italic>vitro</italic> and in vivo</article-title>. <source>J Immunol</source>. (<year>1990</year>) <volume>145</volume>:<page-range>3412&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4049/jimmunol.145.10.3412</pub-id>
</citation>
</ref>
<ref id="B30">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Licona-Limon</surname> <given-names>P</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>LK</given-names>
</name>
<name>
<surname>Palm</surname> <given-names>NW</given-names>
</name>
<name>
<surname>Flavell</surname> <given-names>RA</given-names>
</name>
</person-group>. <article-title>TH2, allergy and group 2 innate lymphoid cells</article-title>. <source>Nat Immunol</source>. (<year>2013</year>) <volume>14</volume>:<page-range>536&#x2013;42</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/ni.2617</pub-id>
</citation>
</ref>
<ref id="B31">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rossi</surname> <given-names>GA</given-names>
</name>
<name>
<surname>Ballarini</surname> <given-names>S</given-names>
</name>
<name>
<surname>Salvati</surname> <given-names>P</given-names>
</name>
<name>
<surname>Sacco</surname> <given-names>O</given-names>
</name>
<name>
<surname>Colin</surname> <given-names>AA</given-names>
</name>
</person-group>. <article-title>Alarmins and innate lymphoid cells 2 activation: A common pathogenetic link connecting respiratory syncytial virus bronchiolitis and later wheezing/asthma</article-title>? <source>Pediatr Allergy Immunol</source>. (<year>2022</year>) <volume>33</volume>:<elocation-id>e13803</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/pai.13803</pub-id>
</citation>
</ref>
<ref id="B32">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kwon</surname> <given-names>YM</given-names>
</name>
<name>
<surname>Hwang</surname> <given-names>HS</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>JS</given-names>
</name>
<name>
<surname>Ko</surname> <given-names>EJ</given-names>
</name>
<name>
<surname>Yoo</surname> <given-names>SE</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>MC</given-names>
</name>
<etal/>
</person-group>. <article-title>Maternal antibodies by passive immunization with formalin inactivated respiratory syncytial virus confer protection without vaccine-enhanced disease</article-title>. <source>Antiviral Res</source>. (<year>2014</year>) <volume>104</volume>:<fpage>1</fpage>&#x2013;<lpage>6</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.antiviral.2014.01.008</pub-id>
</citation>
</ref>
<ref id="B33">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Patel</surname> <given-names>KR</given-names>
</name>
<name>
<surname>Roberts</surname> <given-names>JT</given-names>
</name>
<name>
<surname>Barb</surname> <given-names>AW</given-names>
</name>
</person-group>. <article-title>Multiple Variables at the Leukocyte Cell Surface Impact Fc gamma Receptor-Dependent Mechanisms</article-title>. <source>Front Immunol</source>. (<year>2019</year>) <volume>10</volume>:<elocation-id>223</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2019.00223</pub-id>
</citation>
</ref>
<ref id="B34">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Subedi</surname> <given-names>GP</given-names>
</name>
<name>
<surname>Barb</surname> <given-names>AW</given-names>
</name>
</person-group>. <article-title>The structural role of antibody N-glycosylation in receptor interactions</article-title>. <source>Structure</source>. (<year>2015</year>) <volume>23</volume>:<page-range>1573&#x2013;83</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.str.2015.06.015</pub-id>
</citation>
</ref>
<ref id="B35">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname> <given-names>LL</given-names>
</name>
<name>
<surname>Suscovich</surname> <given-names>TJ</given-names>
</name>
<name>
<surname>Fortune</surname> <given-names>SM</given-names>
</name>
<name>
<surname>Alter</surname> <given-names>G</given-names>
</name>
</person-group>. <article-title>Beyond binding: antibody effector functions in infectious diseases</article-title>. <source>Nat Rev Immunol</source>. (<year>2018</year>) <volume>18</volume>:<fpage>46</fpage>&#x2013;<lpage>61</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nri.2017.106</pub-id>
</citation>
</ref>
<ref id="B36">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McEwan</surname> <given-names>WA</given-names>
</name>
<name>
<surname>Tam</surname> <given-names>JC</given-names>
</name>
<name>
<surname>Watkinson</surname> <given-names>RE</given-names>
</name>
<name>
<surname>Bidgood</surname> <given-names>SR</given-names>
</name>
<name>
<surname>Mallery</surname> <given-names>DL</given-names>
</name>
<name>
<surname>James</surname> <given-names>LC</given-names>
</name>
</person-group>. <article-title>Intracellular antibody-bound pathogens stimulate immune signaling <italic>via</italic> the Fc receptor TRIM21</article-title>. <source>Nat Immunol</source>. (<year>2013</year>) <volume>14</volume>:<page-range>327&#x2013;36</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/ni.2548</pub-id>
</citation>
</ref>
<ref id="B37">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rhodes</surname> <given-names>DA</given-names>
</name>
<name>
<surname>Isenberg</surname> <given-names>DA</given-names>
</name>
</person-group>. <article-title>TRIM21 and the function of antibodies inside cells</article-title>. <source>Trends Immunol</source>. (<year>2017</year>) <volume>38</volume>:<page-range>916&#x2013;26</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.it.2017.07.005</pub-id>
</citation>
</ref>
<ref id="B38">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dunkelberger</surname> <given-names>JR</given-names>
</name>
<name>
<surname>Song</surname> <given-names>WC</given-names>
</name>
</person-group>. <article-title>Complement and its role in innate and adaptive immune responses</article-title>. <source>Cell Res</source>. (<year>2010</year>) <volume>20</volume>:<fpage>34</fpage>&#x2013;<lpage>50</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/cr.2009.139</pub-id>
</citation>
</ref>
<ref id="B39">
<label>39</label>
<citation citation-type="book">
<person-group person-group-type="editor">
<name>
<surname>Kenneth M Murphy</surname> <given-names>CW</given-names>
</name>
<name>
<surname>Berg</surname> <given-names>LJ</given-names>
</name>
</person-group> eds. <source>Janeway's Immunobiology</source> Vol. <volume>10</volume>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Norton &amp; Company</publisher-name> (<year>2022</year>).</citation>
</ref>
<ref id="B40">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pihlgren</surname> <given-names>M</given-names>
</name>
<name>
<surname>Fulurija</surname> <given-names>A</given-names>
</name>
<name>
<surname>Villiers</surname> <given-names>MB</given-names>
</name>
<name>
<surname>Tougne</surname> <given-names>C</given-names>
</name>
<name>
<surname>Lambert</surname> <given-names>PH</given-names>
</name>
<name>
<surname>Villiers</surname> <given-names>CL</given-names>
</name>
<etal/>
</person-group>. <article-title>Influence of complement C3 amount on IgG responses in early life: immunization with C3b-conjugated antigen increases murine neonatal antibody responses</article-title>. <source>Vaccine</source>. (<year>2004</year>) <volume>23</volume>:<page-range>329&#x2013;35</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.vaccine.2004.06.010</pub-id>
</citation>
</ref>
<ref id="B41">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gour</surname> <given-names>N</given-names>
</name>
<name>
<surname>Smole</surname> <given-names>U</given-names>
</name>
<name>
<surname>Yong</surname> <given-names>HM</given-names>
</name>
<name>
<surname>Lewkowich</surname> <given-names>IP</given-names>
</name>
<name>
<surname>Yao</surname> <given-names>N</given-names>
</name>
<name>
<surname>Singh</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>C3a is required for ILC2 function in allergic airway inflammation</article-title>. <source>Mucosal Immunol</source>. (<year>2018</year>) <volume>11</volume>:<page-range>1653&#x2013;62</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41385-018-0064-x</pub-id>
</citation>
</ref>
<ref id="B42">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lefrancais</surname> <given-names>E</given-names>
</name>
<name>
<surname>Duval</surname> <given-names>A</given-names>
</name>
<name>
<surname>Mirey</surname> <given-names>E</given-names>
</name>
<name>
<surname>Roga</surname> <given-names>S</given-names>
</name>
<name>
<surname>Espinosa</surname> <given-names>E</given-names>
</name>
<name>
<surname>Cayrol</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Central domain of IL-33 is cleaved by mast cell proteases for potent activation of group-2 innate lymphoid cells</article-title>. <source>Proc Natl Acad Sci U S A</source>. (<year>2014</year>) <volume>111</volume>:<page-range>15502&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1073/pnas.1410700111</pub-id>
</citation>
</ref>
<ref id="B43">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lefrancais</surname> <given-names>E</given-names>
</name>
<name>
<surname>Roga</surname> <given-names>S</given-names>
</name>
<name>
<surname>Gautier</surname> <given-names>V</given-names>
</name>
<name>
<surname>Gonzalez-de-Peredo</surname> <given-names>A</given-names>
</name>
<name>
<surname>Monsarrat</surname> <given-names>B</given-names>
</name>
<name>
<surname>Girard</surname> <given-names>JP</given-names>
</name>
<etal/>
</person-group>. <article-title>IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G</article-title>. <source>Proc Natl Acad Sci U S A</source>. (<year>2012</year>) <volume>109</volume>:<page-range>1673&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1073/pnas.1115884109</pub-id>
</citation>
</ref>
<ref id="B44">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liew</surname> <given-names>FY</given-names>
</name>
<name>
<surname>Girard</surname> <given-names>JP</given-names>
</name>
<name>
<surname>Turnquist</surname> <given-names>HR</given-names>
</name>
</person-group>. <article-title>Interleukin-33 in health and disease</article-title>. <source>Nat Rev Immunol</source>. (<year>2016</year>) <volume>16</volume>:<page-range>676&#x2013;89</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nri.2016.95</pub-id>
</citation>
</ref>
<ref id="B45">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ward</surname> <given-names>PA</given-names>
</name>
</person-group>. <article-title>Immune complex injury of the lung</article-title>. <source>Am J Pathol</source>. (<year>1979</year>) <volume>97</volume>:<fpage>85</fpage>&#x2013;<lpage>92</lpage>.</citation>
</ref>
<ref id="B46">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Junker</surname> <given-names>F</given-names>
</name>
<name>
<surname>Gordon</surname> <given-names>J</given-names>
</name>
<name>
<surname>Qureshi</surname> <given-names>O</given-names>
</name>
</person-group>. <article-title>Fc gamma receptors and their role in antigen uptake, presentation, and T cell activation</article-title>. <source>Front Immunol</source>. (<year>2020</year>) <volume>11</volume>:<elocation-id>1393</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2020.01393</pub-id>
</citation>
</ref>
<ref id="B47">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hepworth</surname> <given-names>MR</given-names>
</name>
<name>
<surname>Monticelli</surname> <given-names>LA</given-names>
</name>
<name>
<surname>Fung</surname> <given-names>TC</given-names>
</name>
<name>
<surname>Ziegler</surname> <given-names>CG</given-names>
</name>
<name>
<surname>Grunberg</surname> <given-names>S</given-names>
</name>
<name>
<surname>Sinha</surname> <given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Innate lymphoid cells regulate CD4+ T-cell responses to intestinal commensal bacteria</article-title>. <source>Nature</source>. (<year>2013</year>) <volume>498</volume>:<page-range>113&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nature12240</pub-id>
</citation>
</ref>
<ref id="B48">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Drake</surname> <given-names>LY</given-names>
</name>
<name>
<surname>Iijima</surname> <given-names>K</given-names>
</name>
<name>
<surname>Kita</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>Group 2 innate lymphoid cells and CD4+ T cells cooperate to mediate type 2 immune response in mice</article-title>. <source>Allergy</source>. (<year>2014</year>) <volume>69</volume>:<page-range>1300&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/all.12446</pub-id>
</citation>
</ref>
<ref id="B49">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oliphant</surname> <given-names>CJ</given-names>
</name>
<name>
<surname>Hwang</surname> <given-names>YY</given-names>
</name>
<name>
<surname>Walker</surname> <given-names>JA</given-names>
</name>
<name>
<surname>Salimi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Wong</surname> <given-names>SH</given-names>
</name>
<name>
<surname>Brewer</surname> <given-names>JM</given-names>
</name>
<etal/>
</person-group>. <article-title>MHCII-mediated dialog between group 2 innate lymphoid cells and CD4(+) T cells potentiates type 2 immunity and promotes parasitic helminth expulsion</article-title>. <source>Immunity</source>. (<year>2014</year>) <volume>41</volume>:<page-range>283&#x2013;95</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.immuni.2014.06.016</pub-id>
</citation>
</ref>
<ref id="B50">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ukkonen</surname> <given-names>P</given-names>
</name>
<name>
<surname>Lewis</surname> <given-names>V</given-names>
</name>
<name>
<surname>Marsh</surname> <given-names>M</given-names>
</name>
<name>
<surname>Helenius</surname> <given-names>A</given-names>
</name>
<name>
<surname>Mellman</surname> <given-names>I</given-names>
</name>
</person-group>. <article-title>Transport of macrophage Fc receptors and Fc receptor-bound ligands to lysosomes</article-title>. <source>J Exp Med</source>. (<year>1986</year>) <volume>163</volume>:<page-range>952&#x2013;71</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1084/jem.163.4.952</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>